netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 11: Eye - Full Chapter
11.05  Expand sub section  Mydriatics and cycloplegics
11.05  Expand sub section  Antimuscarinics
Atropine + Adrenaline + Procaine 0.3mL subconjunctival injection
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Formulary

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for rapid dilatation of pupil (atropine 0.5mg with adrenaline 1 in 1,000 0.06mL with procaine 3mg; atropine 1mg with adrenaline 1 in 1,000 0.12mL with procaine 6mg)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
Atropine eye drops
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Formulary

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Approved for mydriasis and cycloplegia (1% only)
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Eye-drops 0.5% not available
 
   
Atropine eye drops - preservative free
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Formulary

Provider notes

  • NMUH:
    • No restriction stated (single-use drops)
  • RFL:
    • Approved for mydriasis and cycloplegia (single-use drops + bottle)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated (single-use drops)
 
   
Cyclopentolate eye drops
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Formulary

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Approved for mydriasis and cycloplegia (0.5% & 1%)
  • RNOH:
  • UCLH:
  • WH:
    • No restriction stated
 
   
Cyclopentolate eye drops - preservative free
View adult BNF View SPC online View childrens BNF
Formulary

Provider notes

  • NMUH:
    • No restriction stated (single-use drops)
  • RFL:
    • Mydriasis and cycloplegia (0.5% + 1% single-use drops & 1% bottles)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated (single-use drops)
 
   
Homatropine 1% eye drops
View adult BNF View SPC online View childrens BNF
Formulary

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Approved for mydriasis and cycloplegia
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
Tropicamide eye drops
(Ophthalmic)
View adult BNF View SPC online View childrens BNF
Formulary

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Approved for mydriasis and cycloplegia (1%)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
   
Tropicamide eye drops - single use
View adult BNF View SPC online View childrens BNF
Formulary

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Approved for mydriasis and cycloplegia (0.5% & 1%)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
   
Homatropine 1% eye drops - preservative free
View adult BNF View SPC online View childrens BNF
Unlicensed Drug Unlicensed

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Approved for mydriasis and cycloplegia
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Preservative free Eye-drops Eye-drops 1% (Moorfields’ special)
 
   
11.05  Expand sub section  Sympathomimetics
 ....
 Non Formulary Items
Cyclopentolate eye spray
(Ophthalmic)

View adult BNF View SPC online View childrens BNF
Non Formulary

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
  • UCLH:
  • WH:
    • Non-formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

GP - 1st

Medicines suitable for first-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - 2nd

Medicines suitable for second-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.  

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf

  

GP - Grey

Medicines on hospital formularies which have not been reviewed for suitability in primary care.  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary